CYP Cocktail

DRUG3 trials

Sponsors

Chonbuk National University Hospital, Moleac Pte Ltd., Taiho Oncology, Inc.

Conditions

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsHealthyStroke

Phase 1

Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers

CompletedNCT02056743

Chonbuk National University HospitalHealthy

Start: 2013-09-30Updated: 2014-02-06

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

CompletedNCT04233437

Moleac Pte Ltd.Stroke

Start: 2020-02-10End: 2020-05-16Updated: 2020-09-03

Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

RecruitingNCT05967689

Taiho Oncology, Inc.Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Start: 2023-07-31End: 2028-12-31Target: 220Updated: 2026-09-01

Related Papers

REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (<i>EGFR</i>) mutations.

Journal of Clinical Oncology2024-06-011 citations

Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers.

2015-12-1732 citations